- Home
- RUM vs NVCR Comparison
RUM vs NVCR Comparison
Compare RUM & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RUM
- NVCR
- Stock Information
- Founded
- RUM 2013
- NVCR 2000
- Country
- RUM United States
- NVCR Switzerland
- Employees
- RUM N/A
- NVCR N/A
- Industry
- RUM Computer Software: Prepackaged Software
- NVCR Medical/Dental Instruments
- Sector
- RUM Technology
- NVCR Health Care
- Exchange
- RUM Nasdaq
- NVCR Nasdaq
- Market Cap
- RUM 2.9B
- NVCR 1.9B
- IPO Year
- RUM N/A
- NVCR 2015
- Fundamental
- Price
- RUM $8.99
- NVCR $17.77
- Analyst Decision
- RUM Buy
- NVCR Buy
- Analyst Count
- RUM 2
- NVCR 7
- Target Price
- RUM $15.00
- NVCR $32.43
- AVG Volume (30 Days)
- RUM 3.3M
- NVCR 1.5M
- Earning Date
- RUM 08-11-2025
- NVCR 07-24-2025
- Dividend Yield
- RUM N/A
- NVCR N/A
- EPS Growth
- RUM N/A
- NVCR N/A
- EPS
- RUM N/A
- NVCR N/A
- Revenue
- RUM $101,461,524.00
- NVCR $621,711,000.00
- Revenue This Year
- RUM $19.22
- NVCR $5.56
- Revenue Next Year
- RUM $36.85
- NVCR $9.19
- P/E Ratio
- RUM N/A
- NVCR N/A
- Revenue Growth
- RUM 25.14
- NVCR 18.27
- 52 Week Low
- RUM $4.92
- NVCR $14.17
- 52 Week High
- RUM $17.40
- NVCR $34.13
- Technical
- Relative Strength Index (RSI)
- RUM 49.72
- NVCR 52.02
- Support Level
- RUM $8.92
- NVCR $16.81
- Resistance Level
- RUM $9.81
- NVCR $18.70
- Average True Range (ATR)
- RUM 0.48
- NVCR 0.73
- MACD
- RUM 0.01
- NVCR 0.04
- Stochastic Oscillator
- RUM 51.04
- NVCR 62.75
About RUM Rumble Inc.
Rumble Inc is a free-to-use video-sharing platform where users can watch, share, like, comment, and upload their own videos. Users can subscribe to channels to stay in touch with recent creator content and access video-on-demand uploaded, and live content streamed, by creators. Geographically, it generates a majority of its revenue from the United States.
About NVCR NovoCure Limited
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.